Company intelligence / Profile preview

Carbylan Therapeutics

Palo Alto, California, United Statesir.kalvista.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Carbylan’s lead program was Hydros‑TA—a proprietary intra-articular injectable combining hyaluronic acid and triamcinolone acetonide—developed for pain associated with osteoarthritis of the knee. The company completed a pivotal Phase 3 trial (COR1.1) but suspended further clinical development in April 2016 following disappointing results.[9][6] Subsequently, Carbylan merged with KalVista Pharmaceuticals in late 2016 and ceased independent operations.[1][10]

Therapeutic areas: Rheumatology
Modalities: Combination drug/device productsIntra-articular injectablesSmall molecules (historically; post-merger focus shifted to small molecule protease inhibitors under KalVista)[2][1]
Industry: Biotech

Beyond the preview

Go deeper on Carbylan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carbylan Therapeutics.

Explore the full profile